Bizzell Provides Access to Safe Drinking Water for Children in Africa

Bizzell Provides Access to Safe Drinking Water for Children in Africa

January 11, 2021 (Lanham, MD) – The Bizzell Group (Bizzell) continues to lead in their commitment to improving lives globally, including some of the most vulnerable children in developing countries. Bizzell recently donated water tanks and sinks for young children living in Leve Moi Orphanage in Goma, the Democratic Republic of the Congo (DRC). Leve Moi Orphanage was founded to serve children orphaned by natural and manmade disasters. The orphanage does not receive any state funding and relies on the goodwill of donors like Bizzell to develop and sustain their essential services to the children of the community. Leve Moi Orphanage currently houses 69 children ages 0-17. They also support an additional 500 children from the surrounding community with free education and school meals.

“Clean, safe, and accessible drinking water, a vital natural resource, is critical to human health and sustainable communities, yet dangerously scarce in many parts of the world,” said Rose Amolo, Bizzell’s Director of Global Programs & Strategic Partnerships. “Clean drinking water and handwashing are essential components of health and reduce incidence and spread of infectious diseases and illnesses such as Ebola, COVID-19, and other health conditions at high risk of spread. Bizzell’s donation will directly impact the health outcomes of these children and their community.”

Bizzell’s global philanthropic efforts focus on the provision of effective, efficient, timely, and fiscally responsible health, youth, and economic solutions that improve the overall quality of life for people in low, emerging, and middle-income countries. Using a participatory approach, Bizzell’s experts leverage best practices and methodologies from work with various federal agencies and multinational organizations to effect change. Bizzell integrates diversity in all global activities and recognizes and builds on the inherent knowledge, cultural insights, and expertise of local communities to develop data-driven, research-informed, innovative solutions.

Bizzell’s most recent work in the DRC includes projects with the Centers for Disease Control and Prevention (CDC), international coalitions, and local health agencies, to combat both the Ebola COVID-19 pandemics through medical, epidemiological, technical assistance, and transportation/logistics support. Bizzell’s donation to the Leve Moi orphanage continues our commitment to integrating our subject matter expertise and our philanthropic focus to build healthy, secure, connected, and sustainable communities around the world.

About Bizzell

Established in 2010, The Bizzell Group (Bizzell) is a U.S. Small Business Administration (SBA) 8(a) strategy, technology, and consulting firm. Starting with our passion to improve lives, Bizzell has evolved as a leader in some of the most exciting and critical issues of our time, including training thousands of opioid treatment providers, tackling the Ebola epidemic in the Democratic Republic of the Congo, creating new ways to reach U.S. military members at risk of suicide, and promoting and securing global health. Under the leadership and vision of founder, Dr. Anton C. Bizzell, the company has grown from a staff of two in one small office to a thriving firm with offices in New Carrollton and Rockville, MD; Atlanta, GA; Democratic Republic of the Congo; and Lagos, Nigeria; with many more projects around the world.

Dr. Bizzell Speaks About the First FDA-Approved Treatment for Ebola

Dr. Bizzell Speaks About the First FDA-Approved Treatment for Ebola

Dr. Anton C. Bizzell shares his insights in the Verywell Health article, “Regeneron Earns First-Ever FDA Approval For Ebola Treatment,” about the U.S. Food and Drug Administration (FDA) approval of Inmazeb, an antibody cocktail designed to treat the Ebola virus. A mixture of three monoclonal antibodies administered via injection is the first FDA-approved treatment for the virus. The drug is manufactured by Regeneron, the same company behind the antibody cocktail aimed at treating COVID-19. The Bizzell Group (Bizzell) has been on the ground fighting the Ebola virus in the Democratic Republic of Congo. “The approval of Inmazeb is not only a big deal, it is the approach to prevent a future Ebola pandemic worldwide,” Dr. Bizzell tells Verywell.

READ MORE: Regeneron Earns First-Ever FDA Approval For Ebola Treatment

Lessons for COVID-19 Recovery From the Ebola Epidemic

Lessons for COVID-19 Recovery From the Ebola Epidemic

In a recent Psychology Today article, Dr. Anton C. Bizzell highlights some of the lessons The Bizzell Group (Bizzell) learned during the most recent Ebola virus epidemic. Bizzell partnered with local, national, and international groups to improve health outcomes and mental health consequences in the Democratic Republic of Congo. These lessons can help address the global mental health crisis already emerging due to COVID-19.

“We cannot focus solely on the transmission of COVID-19,” Dr. Bizzell writes. “We must formulate an innovative and sustainable response that addresses the global mental health crisis already emerging.”

READ MORE: Lessons for COVID-19 Recovery From the Ebola Epidemic

17th World Conference on Tobacco or Health

17th World Conference on Tobacco or Health

Project Director Jenny Twesten traveled to Cape Town, South Africa to represent the National Cancer Institute’s Tobacco Control Research Branch at WCTOH held March 6-9, 2018. This international conference drew participants from around the world, with a particularly strong presence from those across Africa, an area where prevalence of cigarette smoking is on the rise and expected to continue to do so without strong tobacco control interventions. The Bizzell Group (Bizzell) supported meeting logistics for a pre-conference workshop entitled “Research to Inform the Development and Implementation of Tobacco Control Policies and Intervention” that was attended by at least 53 people from 23 different countries.

Bizzell also coordinated the NCI presence in the exhibit hall in collaboration with the Centers for Disease Control and Prevention, which nearly ran out of materials within 4 hours of the exhibit hall opening. In addition to attending sessions on electronic nicotine delivery systems (ENDS), economic and social costs of tobacco among women, tools for monitoring tobacco use, and ending the tobacco epidemic, Jenny presented on the Africa literature review that she and Katie Cleffi have been working on with NCI and met with various organizations and experts to discuss collaboration opportunities with NCI. The abstract presented has been published in a special supplement of Tobacco Induced Diseases. She will be presenting along with the other NCI delegates at an upcoming seminar on April 17 hosted by the NCI Center for Global Health to share insights from their WCTOH attendance.